TABLE 3
Glutathione-dasatinib/analog adducts
The modification in boldface represents the most intense signal.
Dasatinib-Glutathione Adducts Modification of Chloromethylphenyl | ||||||||
|---|---|---|---|---|---|---|---|---|
 | ||||||||
| Compound | R | Modification | Parent m/z | Major Fragment Masses | ||||
| Dasatinib |
| +GSH | 793 | 775, 664, 520, 486, 433, 347, 319 | ||||
| +GSH, +O | 809 | 791, 680, 536, 449, 347, 319, 234, 260 | ||||||
| +GSH, +2O | 825 | 807, 696, 552, 465, 347, 319, 234, 260 | ||||||
| 1698 |
| +GSH, +O | 813 | 795, 684, 540, 453, 347, 319, 260, 234 | ||||
| +GSH, +2O | 829 | 811, 701, 556, 469, 436, 347, 319, | ||||||
| 1660 |
| +GSH | 807 | 789, 678, 534, 500, 447, 347, 319, 260 | ||||
| 1695 |
| +GSH | 773 | 755, 644, 500, 413, 347, 319 | ||||
| +GSH, +O | 789 | 771, 660, 516, 429, 347, 319, 260, 234 | ||||||
| +GSH, +2O | 805 | 787, 676, 532, 514, 445, 319, 347, 234 | ||||||
| 1701 |
| +GSH | 791 | 773, 662, 518, 347, 319 | ||||
| +GSH, -F + OH | 789 | 771, 660, 516, 429, 347, 319, 234 | ||||||
| +GSH, -F + O + OH | 805 | 787, 676, 532, 514, 445, 347, 319, 260, 234 | ||||||
| 5826 |
| +GSH | 811 | 793, 682, 579, 538, 451, 347, 319 | ||||
| +GSH, -F + OH | 809 | 791, 680, 536, 449, 347, 319, 260, 234 | ||||||
| +GSH, -F + O + OH | 825 | 807, 696, 552, 465, 347, 319, 234, 260 | ||||||
| 1776 |
| +GSH, +O | 829 | 811, 700, 556, 469, 429, 347, 319, 260 | ||||
| 6704 |
| +GSH | 793 | 775, 664, 486, 347, 319 | ||||
|
|
|
+GSH, -Cl + OH
| 775 | 757, 646, 502, 415, 347, 319, 234 | ||||
| No adducts were detected at concentrations up to 40 μM for | ||||||||
|
|
|
| |||||
| 1250 | 1260 | 1332 | 1622 | |||||